ERBB3 and breast cancer: Wang et al. found that the class I HDAC (histone deacetylase) inhibitor entinostat induced miR-125b expression and subsequently downregulated ERBB2 and ERBB3 expression, leading to cell apoptosis in breast cancer cells [52].